Tukysa®

Active substance

tucatinib (ONT-380)

Holder

Seagen

Status

Running

Indication

in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2 positive locally advanced or metastatic breast cancer who have received at least 2 prior anti HER2 treatment regimens.

Public documents 

Approbation

Information for the patient

Informed consent

Last update

10/08/2022

Last updated on 28/09/2022